Technology | Vascular Access | August 10, 2016

Access Scientific Debuts PowerWand XL Midline Catheter

Catheter designed specifically for component-based, over-wire insertion technique similar to MST

Access Scientific, PowerWand XL midline catheter

August 10, 2016 — Access Scientific introduced the PowerWand XL, a companion to the PowerWand All-in-One, in July. The Powerwand XL is designed specifically for clinicians who prefer to use a component-based, over-wire insertion technique similar to the Modified Seldinger Technique (MST) they currently use.

The XL technique feels similar to the MST, but XL advantages include:

  • Improves clinical outcomes through atraumatic catheter insertion;
  • Designed to reduce risk of deep-vein thrombosis by up to 500 percent. No trimming of catheter necessary;
  • Reduces risk of back leaking. No peel-away sheath;
  • Guidewire extends fully so the catheter does not drag across the intima of the vessel; and
  • Faster and safer because of fewer steps.

As with MST insertions, the XL insertion technique utilizes a 21-gauge safety needle and guidewire to access the vessel. The XL accelerates line placement and makes it safer compared to MST, according to Access Scientific, by eliminating the need for a peelable introducer sheath. Instead, the proprietary PowerWand XL dilator and catheter are inserted directly over the wire and into the bloodstream. This technique eliminates the sheath-related steps in MST that can be associated with such risks as bleeding, back-leaking and vessel damage.

The All-in-One is inserted with the Accelerated Seldinger Technique (AST), which also improves on the MST in speed, number of steps and safety.

Other attributes of the PowerWand XL include:

  • Size: 4Fr and 5Fr;
  • Length: 8 and 10cm;
  • Infection Prevention: Zero BSIs over 12,000 catheter-days;
  • High Flow: Capable of delivering large volumes rapidly, 130-180 ml/min;
  • Power Injectable: 325psi / 8ml per second;
  • Blood Drawable: Allows for blood draws in most patients, 60 – 99 percent; and
  • Patient Satisfaction: Provides patients with one-stick hospitalization.

For more information:

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init